Listar por autor "Kapelios, Chris J."
Mostrando ítems 1-3 de 3
-
Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry
Kapelios, Chris J.; Laroche, Cécile; Crespo-Leiro, María Generosa; Anker, Stefan; Coats, Andrew J.S.; Díaz-Molina, Beatriz; Filippatos, Gerasimos; Lainscak, Mitja; Maggioni, Aldo P.; McDonagh, Theresa A.; Mebazaa, Alexandre; Metra, Marco; Moura, Brenda; Mullens, Wilfried; Piepoli, Massimo F.; Rosano, Giuseppe; Ruschitzka, Frank; Seferovic, Petar M.; Lund, Lars H. (Willey Online Library, 2020-04-01)[Abstract] Aims. Guidelines recommend down-titration of loop diuretics (LD) once euvolaemia is achieved. In outpatients with heart failure (HF), we investigated LD dose changes in daily cardiology practice, agreement ... -
Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry
Kapelios, Chris J.; Benson, Lina; Crespo-Leiro, María Generosa; Anker, Stefan; Coats, Andrew J.S.; Chioncel, Ovidiu; Filippatos, Gerasimos; Lainscak, Mitja; McDonagh, Theresa; Mebazaa, Alexandre; Metra, Marco; Piepoli, Massimo F.; Rosano, Giuseppe M.C.; Ruschitzka, Frank; Savarese, Gianluigi; Seferovic, Petar M.; Volterrani, Maurizio; Maggioni, Aldo P.; Lund, Lars H. (2023-03-04) -
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world
Kapelios, Chris J.; Lainscak, Mitja; Savarese, Gianluigi; Laroche, Cécile; Seferovic, Petar; Ruschitzka, Frank; Coats, Andrew; Anker, Stefan; Crespo-Leiro, María Generosa; Filippatos, Gerasimos; Piepoli, Massimo; Rosano, Giuseppe; Zanolla, Luisa; Aguiar, Carlos; Murin, Jan; Leszek, Przemyslaw; McDonagh, Theresa; Maggioni, Aldo P.; Lund, Lars H. (Wiley, 2019-05-27)[Abstract] Aims: To assess the proportion of patients with heart failure and reduced ejection fraction (HFrEF) who are eligible for sacubitril/valsartan (LCZ696) based on the European Medicines Agency/Food and Drug ...